Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2006

View Archived Issues

Targeting IGF-1R shows antitumor efficacy in mouse models of lung cancer

Ruboxistaurin reduces the risk of vision loss in diabetic retinopathy

Licorice component protects mice against DMN-induced lung and colon tumors

Efficacy of targeting the adenosine A3 receptor shown in patients with rheumatoid arthritis

Targets in nephrology

Novel preclinical data on Zyflamend's antitumor mechanism

Davanat studied in phase II first-line colorectal cancer study

GV-1001 begins phase II trial in liver cancer

FDA accepts complete response for Factive in five-day treatment of CAP

QSC-001 begins clinical program

Kamada begins phase I trials with inhaled API product for congenital emphysema

Neose receives milestone payment under Factor VIIa agreement with Novo Nordisk

Biota and Boehringer Ingelheim enter HCV licensing agreement

First generic ondansetron injection products approved in U.S.

Lundbeck and Biotie sign agreement for nalmefene

Novartis presents pipeline review

No reported increase in Tamiflu resistance

Cytokinetics and GSK amend license and collaboration agreement

Biocon working towards launch of antiarthritis drug in India

New pivotal study begins for Clolar in adult AML

Enrollment complete in phase II trial of MitoQ in Parkinson's disease

Sankyo patents novel compounds for transplant rejection, autoimmune diseases, etc.

Novel Rho kinase inhibitors revealed in D. Western Therapeutics patents

TRK-820 filed in Japan for severe uremic pruritus in hemodialysis patients

Recent patents disclose novel agents with potential in the treatment of HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...